Peer-reviewed veterinary case report
How desoxycorticosterone pivalate works in dogs with low adrenal
By Langlois, Daniel K et al.·Published in Journal of veterinary internal medicine·2026·Department of Small Animal Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Pharmacokinetics and pharmacodynamics of desoxycorticosterone pivalate in dogs with hypoadrenocorticism.
- Species:
- dog
Plain-English summary
A group of 21 dogs with newly diagnosed hypoadrenocorticism (HA), a condition where the body doesn't produce enough hormones, were treated with desoxycorticosterone pivalate (DOCP) to help manage their symptoms. The dogs received either a low dose or a standard dose of the medication, and researchers measured how well the drug worked over time. Both doses were effective, but the standard dose showed higher drug levels in the blood. The study suggests that giving the low dose every 5 to 7 weeks is a good treatment plan for most dogs with HA, and pet owners should be cautious about extending the time between doses based only on electrolyte levels.
People also search for: dog hypoadrenocorticism treatment · DOCP for dogs · how often to give DOCP to dogs
Abstract
BACKGROUND: Desoxycorticosterone pivalate (DOCP) is commonly used to treat mineralocorticoid deficiency in dogs with hypoadrenocorticism (HA). HYPOTHESIS/OBJECTIVE: To determine the pharmacokinetics and pharmacodynamics of DOCP. ANIMALS: Twenty-one dogs with newly diagnosed HA. METHODS: Prospective clinical trial. Dogs were randomly assigned to treatment with an SC injection of either 1.1 mg/kg (low-dose) or 2.2 mg/kg (label-dose) DOCP. Blood samples were collected at set time points for measurement of serum drug concentrations, serum electrolyte concentrations, and plasma renin activities (PRAs). A one-compartment model was used to determine pharmacokinetics variables. Pharmacodynamics variables including duration of DOCP action and duration of overtreatment were estimated from serum electrolyte concentrations and PRA. Pharmacokinetics and pharmacodynamics variables were compared between low-dose and label-dose groups. RESULTS: Maximum drug concentrations and overall drug exposures were higher in label-dose dogs (1.22 ± 0.46 ng/mL and 32.1 ± 12.3 day × ng/mL) than in low-dose dogs (0.69 ± 0.32 ng/mL and 19.6 ± 5.3 day × ng/mL; P = .008 for both comparisons). However, duration of DOCP action as determined by PRA in label-dose (55 ± 16 days) and low-dose (45 ± 12 days) dogs was not different (P = .2). Serum electrolyte concentrations overestimated the duration of action in the combined group by a mean of 10 days when compared with PRA (P < .001). CONCLUSIONS AND CLINICAL IMPORTANCE: Pharmacokinetics and pharmacodynamics data suggest that low-dose DOCP administered every 5-7 weeks is a reasonable treatment strategy for most dogs with HA. Prolonging dosing intervals > 7-8 weeks based solely on electrolyte concentrations should be avoided.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41742504/